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The genetic heterogeneity associated with retinal degeneration arises from the large 
number of genes that have been implicated and the variety of mutations which affect them. 
This diversity has driven researchers to develop alternatives to gene replacement strategies 
in order to treat a spectrum of retinal diseases. Complementary strategies also need to be 
devised to adapt to the different stages of the disease, from early treatments to late-stage 
therapies. Thus in parallel to gene replacement techniques, advances in neurotrophic factor 
support and transplantation of photoreceptors into the retina have thus far shown promise. 
The development of a retinal prosthesis has progressed strongly, allowing retinas which are 
entirely devoid of photoreceptors to recover some basic visual input to a brain which has 
already learned to treat that information. In this context, considerable emphasis shoule be 
placed upon the work of Lagali et al and their predecessors who have adapted the function 
of surviving bipolar and retinal ganglion cells to serve as photoreceptors. The transfer of 
photosensitive protein complexes to these cells offers a new vista for the restoration of 
visual function as it evokes brain stimulation and the improvement of visual perception 
(optomotor response). Although much additional work is required to increase the 
sensitivity of this genetically adapted retina and to mimic its normal excitatory mode of 
operation, these early breakthroughs promise exciting potential human applications. 
 
 
Retinal degeneration affects millions of patients throughout the world for whom almost no 
therapy exists. The origin is often genetic and results in two main categories of diseases: the 
hereditary retinal dystrophies (or retinitis pigmentosa) and aged-related macular degeneration. 
During the last years and months important breakthroughs in the ophthalmology field revealed 
that the treatment of certain forms of retinal degeneration can be really efficient to stop the 
disease or even restore visual function. Indeed, three recent studies show that gene replacement 
in young patients, affected by a recessive disease disrupting the RPE65 gene function in the 
pigmented epithelium, can restore some retinal and visual functions (Bainbridge et al., 2008; 
Maguire et al., 2008) and (Jacobson et al., in press). Such results are the proof of principle that 
gene replacement strategy in recessive disease could also be successful for other types of gene 
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mutations. However, for the condition retinitis pigmentosa, around one hundred different 
mutated genes may be responsible for this disease. Until now, 45 different genes have been 
identified as being at the origin of blindness when a mutation alters the function of the encoded 
protein. Fifty other loci might explain other forms of retinal dystrophies (Hartong et al., 2006). In 
total, 60% of the known diseases may be related to these genetic differences. The complexity 
increases upon knowing that a same gene, depending on the mutation that it bears, can provoke 
either a recessive or a dominant form of the disease. These facts reveal the complexity of 
developing a specific therapy for each disease and different strategies are being developed to 
prolong vision in affected patients. 
Different strategies to maintain and restore vision
As an alternative to gene replacement, a neuroprotective approach has been proposed to enhance 
the survival of the affected photoreceptors. Neurotrophic factors and chemical compounds with 
anti-oxidative properties are the main candidates to have been tested until now. Two 
neurotrophic factors have become of prospective interest and either are, or have actually been 
tested in clinical trials: the ciliary neurotrophic factor (CNTF; Sieving et al., 2006; www.
neurotechusa.com/news_press) and the pigmented epithelial derived factor (PEDF; Nguyen et 
al., 2006). To deliver CNTF, human cells were bioengineered to express CNTF cDNA, and those 
clones that were able to secrete reliably CNTF and to survive in vivo within dog eyes, were 
encapsulated in a semi-permeable membrane to prevent immune rejection and to allow the free 
diffusion of the factor and nutrients. Such a device, implanted under the sclera in the dorsal part 
of the eye in patients suffering from various forms of retinitis pigmentosa actually delayed the 
loss of visual acuity in certain patients, leading to the launch of a Phase II/III clinical trial (www.
neurotechusa.com/news_press). PEDF, which has anti-angiogenic as well as neurotrophic 
actions, was tested in a clinical trial using a non-replicative recombinant adenovirus injected 
under the retina to transfer the PEDF coding sequence into the retinal pigmented epithelium. In 
patients suffering from neovascular AMD, PEDF induced the regression of the neo-vessels in 
certain patients and also prevented the loss of visual acuity performances during the first year 
after the treatment (Campochiaro et al., 2006). These experiments reveal that neurotrophic 
factors show promise in slowing down retinal degeneration, but not so far actually preventing it. 
Another clinical strategy seeks to replace lost photoreceptors by generating photoreceptors in 
vitro. The proof of principle of restoring retinal function through cell transplantation was brought 
by MacLaren et al. (2006) who showed after transplantation, in mice at least, that newly 
generated post-mitotic photoreceptors (isolated from postnatal day 3 to 7) have a great ability to 
integrate morphologically and functionally within a healthy or a diseased retina. The grafted cells 
make adequate connections and enhance retinal sensitivity, as well as the pupil light reflex. In 
parallel to this study, several groups attempted to generate adequate cell numbers through using 
different types of stem cells, including those derived from the retina, embryo, bone marrow and 
iris (for review see Pellegrini et al., 2007). Some successes were gained in generating cells that 
became ‘committed’ to a photoreceptor fate (Merhi-Soussi et al., 2006; Osakada et al., 2008; 
Haruta et al., 2001). However, no efficient cell integration into the retina was reported with such 
stem cells (see Pelligrini et al. 2007). Moreover, no successful primary cell transplantation has 
been reported to date for any retina that has lost all its photoreceptors. 
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Can a retina devoid of photoreceptors be reactivated to restore visual functions?
Depending on the nature of the condition, retinal degeneration may be too fast to be stopped with 
actual experimental tools, leading to the total loss of photoreceptors. However, both the 
interneurons and retinal ganglion cells, the latter forming the optic nerve and being the final 
common pathway for retinal signals, may survive quite some time after the loss of 
photoreceptors. Even if a rapid remodelling of the circuitry occurs between the remaining 
neurons (Jones et al., 2003; Strettoi et al., 2002), it is hypothesized that the enduring retinal 
ganglion cells may maintain their capacity to transfer coherent information into the brain if they 
receive the appropriate stimuli. Several groups and biotechnology companies have developed a 
retina prosthesis that is composed of chips containing multiple micro-electrodes. The device is 
directly apposed to the retina at the level of the ganglion cell layer, and is stimulated by the 
electrodes thanks to a camera and an amplifier situated outside the eye (Weiland et al., 2004). 
Over the past decade, it has been shown that acute stimulation of a retina from a blind patient can 
elicit the sensation and perception of light dots termed ‘phosphenes’, and in some better cases, 
the reading of large letters or the observation of a large object in a well contrasted environment is 
possible. Perception of motion has also been reported (Weiland et al., 2004). The main problems 
encountered are: 1) putting sufficient electrodes onto the retina to give an adequate resolution of 
an image; 2) transferring energy to the electrodes; 3) generating a device that remains attached to 
the retina; and 4) developing an intelligent device that can be modulated to generate the best 
picture depending on the structure of the remaining retina. Numerous progressions have been 
made in this field, but these early devices still require further improvements to enable chronic 
implantation. Nonetheless, such results unequivocally provide evidence that the retina of a blind 
person who was previously able to see, may be reactivated to provide some useful information to 
the brain. 
In this context, the paper of Lagali et al. (2008) brings a breakthrough by restoring vision in a 
retina completely devoid of photoreceptors. In 2006, Bi et al. (2006) investigated the possibility 
of rendering the remaining retinal ganglion cells (RGCs) active under light stimulations. The 
goal was to find a molecule which was able to detect photons and to induce the direct 
depolarization of RGCs. Within the photoreceptor, such a mechanism necessitates a cascade of 
numerous proteins from rhodopsin, which traps light energy through its pigment 11-cis-retinal, to 
the sodium and calcium channels which close to hyperpolarize the cell. These graded changes in 
membrane potential lead to neurotransmitter release to activate ON bipolar cells, which in turn 
stimulate RGCs. Bi et al. propose to use an evolutionary ancestor of rhodopsin, ChR2, which is 
found in green algae such as Chlamydomonas. ChR2 is a light-gated cation channel which 
confers two principle properties upon a single protein, namely photosensitivity and a cationic 
conductance through which to depolarize the cell. Using adeno-associated viral vectors, Bi et al., 
genetically engineered the RGCs, horizontal and amacrine cells of Rd1/Rd1 blind mice, which 
characteristically lose all of their rod photoreceptors at around the age of 21 days. Some bipolar 
cells were also infected. The genetically engineered cells respond to light stimuli, and recordings 
taken from the cortical regions suggest signal transmission from the retina to the brain. These 
experiments were remarkable by the fact that they demonstrate that a neuron may be converted 
into a photosensitive cell that stimulates a neuronal network. However, the RGC population 
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usually receives both excitatory and inhibitory inputs that are necessary to pre-construct an image 
which is then sent to the brain for further processing and construction. The approach of Bi et al., 
does not allow the cortex or RGCs to discriminate these fine inputs which convey important 
information concerning such properties as contrast, movement and wavelength. To mimic some 
of the classical photoreceptor outputs onto the inner retina, Lagali et al. (2008) selectively 
targeted the expression of ChR2 within ON bipolar cells, which normally receive direct 
photoreceptor input when activated. To achieve this cell specific expression, the Grm6 promoter, 
which is only active in ON bipolar cells, was included in the transgene construction comprising 
the ChR2 sequence fused with enhanced yellow fluorescent protein cDNA. The resulting plasmid 
construct was electroporated into the retina of newborn Rd1 mice (post-natal day 0-1). In total 
7% ± 3% of all ON bipolar cells expressed this construct. Their identity could readily be 
demonstrated by examining the terminals of the ON bipolar cells which only innervate certain 
synapse boundaries. Using bright light stimuli, they observed different types of RGC spiking 
activity which correlated with the stimulation period. It is however known that synaptic 
remodelling occurs during and after photoreceptor loss (Jones et al., 2003; Strettoi et al., 2002). 
Interestingly, by using different synaptic blockers, the investigators demonstrated that synaptic 
connections between ON bipolar cells and RGCs, or ON bipolar cells and amacrine cells, appear 
to be normal, even 67 days after the treatment. This suggests that the maintenance of ON bipolar 
cell activity may help to prevent synaptic retraction. It is not known if such a reactivation of 
bipolar cells at a later stage (and older age) of retinal degeneration may allow the restoration of 
normal circuitry, although such an approach may be of great potential interest for blind patients 
of a certain period. Nonetheless, it is not clear whether the treated mice conserve a normal 
circuitry between the different classes of interneurons and the RGCs, and further investigations 
are needed to clarify this point. Nevertheless, these experiments show that such genetically 
engineered ON bipolar cells may react to light to elicit different RGC responses. Moreover, 
electrophysiological recordings obtained from the visual cortex reveals that the RGCs 
successfully transmit these light signals to higher brain centres. Even if the activated regions 
shows some differences from wild-type animals, the responsivity of the treated Rd1 mice is 
certainly significantly greater than those seen in the absence of cortical stimulation in Rd1 
control mice. This cortical responsivity in mice that received the ChR2 transgene suggests that 
these animals may even have had a visual perception. Indeed, these mice demonstrated light-
induced changes in motor behaviour and responded to visual stimuli when exposed to a rotating 
drum containing black and white strips (an ‘optomotor response’). It is remarkable that such 
visual restoration is effective when only some 7% of ON bipolar cells are successfully 
transduced to express a detectable level of gene expression. These experiments have paved the 
way to restore ‘picture perception’ by the retina in absence of photoreceptors. Such technology 
appears especially pertinent for patients detected at late stages of retinal degeneration, or for 
those where the gene or gene function related to their condition is unknown. Nonetheless, several 
refinements in the technology have to be attained before such applications may be gainfully 
translated to the treatment of blind persons. 
Perspectives
The sensitivity of the bipolar cells containing ChR2 is very low in comparison to that of rods or 
cone photoreceptors. The engineered cells are in fact 100,000 times less sensitive to light than are 
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cones. The threshold of perception corresponds to bright light, and only highly contrasted objects 
may be perceived. It is difficult to imagine that such sensitivity could confer independent 
mobility upon patients. As a consequence, an increase in the sensitivity of the system has to be 
developed. In parallel, the remaining retinal circuitry has to be ‘requisitioned’ to improve visual 
acuity and contrast. The ideal scenario would be to generate both ON and OFF bipolar cell inputs 
by appropriately engineering these cells which directly target different functional populations of 
RGCs. Synthetic ‘optical neuromodulators’ are already being tested within different neuronal 
systems and appear promising for the retina. 
Such neuromodulators are derived from existing ion channels which have been genetically 
engineered to accept a photosensitive molecule that can be fixed to the external region of the 
receptor. Following light stimulation, reversible photoisomerization modulates the conformation 
of the engineered channels, resulting in changes in their open probability or conductance. This 
approach has led to the creation of photosensitive channels which may depolarize or 
hyperpolarize neurons within neuronal circuits which are not normally light sensitive. For 
example, a glutamate receptor-channel (LiGluR) was engineered to covalently bind a maleimide-
azobenzene-glutamate agonist that activates the receptor under 380 nm stimulation, and inhibits 
it in response to 500 nm light (Gorostiza et al., 2007; Szobota et al., 2007). This synthetic 
receptor, when used to genetically engineer zebra fish sensory neurons, allowed the activity of 
these neurons to be controlled by light stimuli (Szobota et al., 2007). For example, the escape 
response to tactile stimuli could be inhibited via the photoactivation of this receptor. Such 
experiments demonstrate that neuronal activity may be artificially controlled by unnatural stimuli 
thanks to the creation of genetically engineered ion channels. This strategy opens new vistas for 
regaining control of the activity of neurons which have lost their normal sensory or modulatory 
inputs. The work of Lagali et al. (2008) clearly shows that ON bipolar cells which have become 
disconnected from their normal photoreceptor input may still behave appropriately when excited. 
Neuron reactivation was already known to some degree through electrode stimulations of brain 
or retinal tissue through varying stages of neurodegenerative diseases (e.g. Parkinson’s disease, 
retinal degeneration). However, the molecular engineering of specific neurons augurs a level of 
fine neuromodulation which would have been inconceivable at the end of the last Millennium. 
Such a strategy would enable a precise, unlimited and rapid remote control of any neuronal 
population which would not have been possible to achieve with diffusible modulators (Gorostiza 
et al., 2007; Kocer et al., 2005). Much work has still to be done to fine tune the sensitivity of 
these synthetic receptors and to target other cell types, but the recent data generated from the 
genetically engineered retinas of blind mice clearly provide the proof of principle needed to 
promise the restoration of function within a diseased nervous tissue. It remains a widespread 
hope that such nascent technologies may be applied to humans in order to circumvent the 
functional deficits associated with neurodegenerative diseases and nerve injury. 
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Scheme illustrating the various approaches currently in development to treat retinal degeneration. 
During the time course of retinal degeneration (red arrow), the photoreceptor layer thins and eventually 
disappears. This progression defines therapeutic windows (green areas) for which different strategies are 
explored in order to adjust the treatment to the stage of degeneration. Early therapeutic interventions might 
comprise gene replacement or neurotrophic support represented by a viral vector, naked DNA and 
nanoparticles (A). With the disappearance of the photoreceptors, transplantation of new cells becomes crucial 
to replace this missing population (B). At a later stage of degeneration, the last approaches which remain to 
help a retina devoid of phototreceptors to transmit some visual inputs to the brain are implanting a retinal 
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